Magle Biopharma was born out of the discovery of novel stem cells in full term amniotic fluid. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability, tissues and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries. 

The science and research behind the discoveries on which the company is based has been carried out within the realms of the reputable Lund University in southern Sweden, one of its prime research centers BMC (Bio Medical Center) Research Center, and the university hospital in Lund. Therefore, Magle Biopharma considers itself today to be uniquely positioned to translate stem cell technologies into novel and improved human therapeutics.

Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections), means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells makes them superior to traditional sources of stem cells that are currently in therapeutic use. 

As part of our commitment to providing the best cell therapeutics we are developing these for treatments  with high unmet needs in collaboration with international renowned KOLs and partners. In a nutshell, we have designed and built a complete ecosystem for managing these cells in a safe, secure and controlled manner, which we are now expanding and scaling up. Our journey continues. We will push the boundaries of science within regenerative medicine to save and improve the lives of many.

#regenerativemedicine, #stemcells #therapies

Magle Biopharma

Org chart

Teams

Offices

Magle Biopharma

Org chart

Teams

Offices

Related companies